This year marks an important milestone for our community as we introduce a new national organizational name that reflects who we are today and who we are becoming.
CLICK HERE to find out the new name and to read all about it.
Our NOVEL THERAPIES EDUCATION PROGRAM now has its own podcast series!
Available in video and audio formats
CLICK HERE for “The potential next therapies for bleeding disorders to enter the Canadian market”
CLICK HERE for “What’s coming for VWD and Glanzmann Thrombasthenia?”
New podcasts discussing hemophilia gene therapy have been released!
Available in video and audio formats
CLICK HERE for EPISODE 12 – Overview of gene therapy approaches
CLICK HERE for EPISODE 13 – If gene therapy for hemophilia B were available tomorrow, would you want to receive it?
CLICK HERE for EPISODE 14 – Four people describe their experiences with hemophilia B gene therapy
CLICK HERE for Episode 15 – Shared decision-making
Time to apply for the James Kreppner Memorial Scholarship and Bursary Program.
CLICK HERE for all the details and to apply.
The CHS Board of Directors is recruiting. Please CLICK HERE for full details and to apply.
Deadline: March 16, 2026.
On January 22, the Canadian Hemophilia Society (CHS) held a virtual Town Hall to present the new strategic priorities for the CHS. Emil Wijnker, CHS President, and Sarah Ford, CEO, were very happy to present the outline of this new chapter for the organization and to announce the upcoming new name of the CHS.
CLICK HERE to watch the recording of the Town Hall.
Drawing on over fifty years of experience, Drs. Card and Poon combine first-hand insights with interviews from more than seventy health care professionals and patients to tell the captivating, in-depth story of hemophilia care in Canada.
CLICK HERE to order your copy.
To follow the development of products in the pipeline, it’s here!
The CHS educational catalogue has been updated.
CLICK HERE to take a look at its dynamic online version or to download it as a PDF.
The CHS is very proud to present its latest publication, the first component of its brand-new Novel Therapies Education Program.
CLICK HERE to access the online booklet.
